Wolverine Asset Management’s abrdn Life Sciences Investors HQL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $152K | Sell |
7,584
-29,751
| -80% | -$526K | ﹤0.01% | 1128 |
|
|
2026
Q1 | $607K | Sell |
37,335
-59,787
| -62% | -$999K | 0.01% | 893 |
|
|
2025
Q4 | $1.63M | Sell |
97,122
-118,399
| -55% | -$1.99M | 0.01% | 652 |
|
|
2025
Q3 | $3.34M | Buy |
215,521
+72,601
| +51% | +$994K | 0.02% | 443 |
|
|
2025
Q2 | $1.83M | Buy |
142,920
+17,382
| +14% | +$214K | 0.02% | 550 |
|
|
2025
Q1 | $1.59M | Buy |
125,538
+4,075
| +3% | +$55.2K | 0.02% | 574 |
|
|
2024
Q4 | $1.59M | Buy |
+121,463
| New | +$1.75M | 0.02% | 583 |
|
|
2024
Q2 | – | Sell |
-14,929
| Closed | -$203K | – | 1701 |
|
|
2024
Q1 | $203K | Sell |
14,929
-192,463
| -93% | -$2.66M | ﹤0.01% | 955 |
|
|
2023
Q4 | $2.79M | Sell |
207,392
-114,766
| -36% | -$1.41M | 0.02% | 462 |
|
|
2023
Q3 | $4.02M | Buy |
322,158
+86,671
| +37% | +$1.14M | 0.05% | 367 |
|
|
2023
Q2 | $3.19M | Sell |
235,487
-70,853
| -23% | -$978K | 0.04% | 393 |
|
|
2023
Q1 | $4.27M | Buy |
306,340
+35,802
| +13% | +$512K | 0.05% | 353 |
|
|
2022
Q4 | $3.84M | Buy |
270,538
+55,266
| +26% | +$801K | 0.04% | 403 |
|
|
2022
Q3 | $2.94M | Buy |
215,272
+62,091
| +41% | +$928K | 0.03% | 459 |
|
|
2022
Q2 | $2.18M | Buy |
153,181
+128,553
| +522% | +$1.94M | 0.02% | 531 |
|
|
2022
Q1 | $407K | Buy |
+24,628
| New | +$424K | ﹤0.01% | 1031 |
|
|
2020
Q3 | – | Sell |
-2,587
| Closed | -$46K | – | 1639 |
|
|
2020
Q2 | $46K | Sell |
2,587
-302,987
| -99% | -$5.19M | ﹤0.01% | 1245 |
|
|
2020
Q1 | $4.58M | Sell |
305,574
-31,975
| -9% | -$524K | 0.07% | 221 |
|
|
2019
Q4 | $5.88M | Buy |
337,549
+118,994
| +54% | +$1.95M | 0.07% | 222 |
|
|
2019
Q3 | $3.3M | Buy |
218,555
+44,027
| +25% | +$705K | 0.04% | 302 |
|
|
2019
Q2 | $2.94M | Sell |
174,528
-7,319
| -4% | -$121K | 0.04% | 350 |
|
|
2019
Q1 | $3.12M | Buy |
181,847
+43,774
| +32% | +$756K | 0.04% | 320 |
|
|
2018
Q4 | $2.09M | Buy |
+138,073
| New | +$2.43M | 0.03% | 537 |
|
|
2018
Q3 | – | Sell |
-60,362
| Closed | -$1.13M | – | 1551 |
|
|
2018
Q2 | $1.13M | Buy |
60,362
+4,872
| +9% | +$91.7K | 0.01% | 727 |
|
|
2018
Q1 | $1.07M | Buy |
+55,490
| New | +$1.11M | 0.01% | 741 |
|
|
2015
Q4 | – | Sell |
-17,723
| Closed | -$398K | – | 1794 |
|
|
2015
Q3 | $398K | Buy |
+17,723
| New | +$496K | 0.01% | 728 |
|
|
2014
Q4 | – | Sell |
-10,820
| Closed | -$239K | – | 2336 |
|
|
2014
Q3 | $239K | Buy |
+10,820
| New | +$235K | 0.01% | 976 |
|
|
2013
Q4 | – | Sell |
-25,122
| Closed | -$483K | – | 2780 |
|
|
2013
Q3 | $483K | Buy |
+25,122
| New | +$481K | 0.01% | 773 |
|
Other funds holding HQL
PCM
NIM
FHA
AAM
1WA
Wolverine Asset Management's HQL Position: Q2 2026 in Review
Wolverine Asset Management reduced its abrdn Life Sciences Investors (HQL) stake by 80% in Q2 2026, selling an estimated $526K and leaving 7,584 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #1128.
Wolverine Asset Management first reported a position in HQL in Q3 2013 and has held it in 28 quarters since. The position peaked at $5.88M in Q4 2019. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.
- Wolverine Asset Management held 7,584 shares of abrdn Life Sciences Investors worth $152K as of Q2 2026.
- Wolverine Asset Management sold 29,751 abrdn Life Sciences Investors shares in Q2 2026, an estimated $526K.
- abrdn Life Sciences Investors made up ﹤0.01% of Wolverine Asset Management's portfolio in Q2 2026, its #1128 holding.
- Wolverine Asset Management first reported a position in abrdn Life Sciences Investors in Q3 2013 and has held it in 28 quarters since.
- Wolverine Asset Management's abrdn Life Sciences Investors position peaked at $5.88M in Q4 2019.
- 83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.
Based on Wolverine Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.